Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Synthesis and Regulation of Thyroid Hormones

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Incorporating the Next Generation of Immunotherapies Into the Treatment of Multiple Myeloma.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same author

De-Escalated Adjuvant Radiation Therapy in Patients With HPV-Positive Oropharyngeal Cancer.

JAMA network open·2026

Same author

Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma.

Blood cancer journal·2026

Same author

IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM.

Blood advances·2026

Same author

First-line Therapy in Newly Diagnosed Multiple Myeloma.

Blood cancer discovery·2026

Same author

Comparison of Gluteus Medius Muscle Activation in Women With and Without Patellofemoral Pain.

Journal of athletic training·2025

Search research articles

Related Experiment Video

Updated: Nov 17, 2025

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

Molecular-Driven Therapy in Advanced Thyroid Cancer.

Kevin C Miller¹, Ashish V Chintakuntlawar²

¹Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.

Current Treatment Options in Oncology

|February 11, 2021

Summary

Targeted therapies and genomics are revolutionizing advanced thyroid cancer treatment by matching patients to specific treatments. Further research and clinical trial enrollment are crucial for improving outcomes in refractory and anaplastic thyroid cancers.

Keywords:

Genomics Immunotherapy Targeted therapy Thyroid cancer

More Related Videos

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Related Experiment Videos

Last Updated: Nov 17, 2025

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Area of Science:

Oncology
Genetics
Molecular Biology

Background:

Understanding the molecular drivers of thyroid cancer has led to significant advancements in treating aggressive and advanced disease.
Current treatment strategies involve matching patients to targeted therapies based on specific mutations or gene fusions.
Genomic profiling plays an increasing role in prognostication to guide treatment decisions.

Purpose of the Study:

To review recent clinical trial findings and preclinical data on molecular-driven therapies for advanced thyroid cancer.
To highlight successes and remaining challenges in the field.
To emphasize the importance of clinical trial participation for advancing patient care.

Main Methods:

Review of recent clinical trials in advanced thyroid cancer.
Summary of promising preclinical data supporting molecular-targeted therapies.
Discussion of the role of genomics in prognostication and treatment selection.

Main Results:

Targeted therapies, such as selective RET inhibitors, show promise for specific patient subsets.
Immune checkpoint inhibitors are being investigated for PD-L1-positive tumors.
MAPK pathway inhibition may enhance responses to radioactive iodine therapy.
Genomic insights are improving prognostication for thyroid tumors.

Conclusions:

Molecular-driven therapies represent a paradigm shift in advanced thyroid cancer treatment.
Despite progress, significant challenges remain, particularly for radioactive-iodine refractory differentiated thyroid cancer and anaplastic thyroid cancer.
Continued research and enrollment in clinical trials are essential for improving patient outcomes.